SEI Investments
ORMP icon

SEI Investments’s Oramed Pharmaceuticals ORMP Stock Holding History

SEI Investments’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-278
Closed -$1K – 2325
2014
Q4 		$1K Buy
+278
New +$1.83K ﹤0.01% 2144

Other funds holding ORMP

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
GIM
Greylin Investment Management Orange, Virginia $598M AUM 18.59% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

SEI Investments's ORMP Position: Q1 2015 in Review

SEI Investments sold out of Oramed Pharmaceuticals (ORMP) in Q1 2015, closing a stake of 278 shares — an estimated $1K sold.

SEI Investments first reported a position in ORMP in Q4 2014 and held it in 1 quarter. The position peaked at $1K in Q4 2014. 17 funds tracked by Wall St. Rank hold ORMP as of Q1 2015.

  • SEI Investments reported no remaining Oramed Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • SEI Investments sold 278 Oramed Pharmaceuticals shares in Q1 2015, an estimated $1K.
  • SEI Investments first reported a position in Oramed Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • SEI Investments's Oramed Pharmaceuticals position peaked at $1K in Q4 2014.
  • 17 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2015.

Based on SEI Investments's 13F filing for Q1 2015, filed 1 May 2015.